Leon M Larcher
Overview
Explore the profile of Leon M Larcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang D, Huang D, Larcher L, Zaw K, Chen S, Jennings L, et al.
Stem Cell Res
. 2024 Dec;
82():103621.
PMID: 39642595
Two human induced pluripotent stem cell lines, LEIi021-A and LEIi021-B, were derived from dermal fibroblasts from a healthy control subject from an Australian Aboriginal family with retinitis pigmentosa-11. Reprogramming was...
2.
Larcher L, Pitout I, Keegan N, Veedu R, Fletcher S
Nucleic Acid Ther
. 2023 Apr;
33(3):178-192.
PMID: 37093127
Nucleic acids drugs have been proven in the clinic as a powerful modality to treat inherited and acquired diseases. However, key challenges including drug stability, renal clearance, cellular uptake, and...
3.
Du R, Wang X, Zhou H, Ma L, Larcher L, Chen C, et al.
Support Care Cancer
. 2022 Nov;
30(12):9889-9899.
PMID: 36400979
Purpose: The status and associated factors of the health-related quality of life of non-small-cell lung cancer (NSCLC) patients under targeted anti-cancer therapy have not been investigated. Self-management and coping style...
4.
Flynn L, Li R, Pitout I, Aung-Htut M, Larcher L, Cooper J, et al.
Front Genet
. 2022 Apr;
13:791416.
PMID: 35464859
Oligonucleotides and nucleic acid analogues that alter gene expression are now showing therapeutic promise in human disease. Whilst the modification of synthetic nucleic acids to protect against nuclease degradation and...
5.
Du R, Wang X, Ma L, Larcher L, Tang H, Zhou H, et al.
BMC Cancer
. 2021 Feb;
21(1):206.
PMID: 33639888
Background: The adverse reactions (ADRs) of targeted therapy were closely associated with treatment response, clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation...
6.
Balachandran A, Larcher L, Chen S, Veedu R
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32906592
Brain cancer is one among the rare cancers with high mortality rate that affects both children and adults. The most aggressive form of primary brain tumor is glioblastoma. Secondary brain...
7.
Du R, Wang P, Ma L, Larcher L, Wang T, Chen C
Health Qual Life Outcomes
. 2020 Jun;
18(1):190.
PMID: 32552846
Background: Return to work following myocardial infarction (MI) represents an important indicator of recovery. However, MI can cause patients to feel pressure, loneliness and inferiority during work and even detachment...
8.
Yang D, Zhang W, Zhang H, Zhang F, Chen L, Ma L, et al.
Theranostics
. 2020 Mar;
10(8):3684-3707.
PMID: 32206116
Exosomes are small extracellular vesicles with diameters of 30-150 nm. In both physiological and pathological conditions, nearly all types of cells can release exosomes, which play important roles in cell...
9.
Development of Novel antimiRzymes for Targeted Inhibition of miR-21 Expression in Solid Cancer Cells
Larcher L, Wang T, Veedu R
Molecules
. 2019 Jul;
24(13).
PMID: 31284665
MicroRNAs (miRNAs) are short non-coding RNAs that are involved in the regulation of gene expression. Previous reports showed an over-expression of miRNA-21 (miR-21) in various cancer cells, and its up-regulation...
10.
Wang T, Chen C, Larcher L, Barrero R, Veedu R
Biotechnol Adv
. 2018 Nov;
37(1):28-50.
PMID: 30408510
Aptamers are short single-stranded nucleic acid sequences capable of binding to target molecules in a way similar to antibodies. Due to various advantages such as prolonged shelf life, low batch...